
SYRE Stock Forecast & Price Target
SYRE Analyst Ratings
Bulls say
Spyre Therapeutics is well-positioned for long-term success in the treatment of immune-based diseases such as inflammatory bowel disease and rheumatoid arthritis, as evidenced by positive clinical trial results and a strong pipeline. The company's YTE half-life extension technology is a key differentiator, potentially leading to improved efficacy and convenience in comparison to competitors' therapies. With an expanded focus on rheumatology and dermatology, as well as potential combination therapies, Spyre has ample opportunities for commercial success and could emerge as a leader in the market. Additionally, the company's clean safety profile and potential for accelerated regulatory approval are positive indicators for future growth.
Bears say
Spyre Therapeutics is facing several challenges, including a lack of near-term catalysts, potential difficulties with ad hoc co-formulation of their drugs, and disappointing results for their SPY072 monotherapy in rheumatoid arthritis. Additionally, while their extended half-life antibody, SPY003, has shown potential in ulcerative colitis, other competitors may have more advanced and/or superior treatments. This, coupled with the company's lack of revenue and limited pipeline, leads to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Spyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SYRE Analyst Forecast & Price Prediction
Start investing in SYRE
Order type
Buy in
Order amount
Est. shares
0 shares